- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05161208
OC-01 (Varenicline) Nasal Spray and Dry Eye Signs and Symptoms in Daily Disposable Contact Lens Wearers
Randomized, Controlled, Double-masked Investigator Initiated Study to Evaluate the Efficacy of OC-01 (Varenicline) Nasal Spray on Objective and Subjective Dry Eye Signs and Symptoms in Daily Disposable Contact Lens Wearers
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10022
- Center for Ophthalmic and Vision Recearch
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Provide signed written consent prior to study-related procedures.
- Be ages 18 to 70 3. Is a symptomatic CL wearer with a CLDEQ-8 score of ≥12 points at baseline at the end of wear time.
4. Soft contact lens wearers with self-reported complaints of dryness and/or reduced contact lens wear time.
5. Wear soft contact lenses 2 or more days a week for more than 1 month in both eyes.
6. Currently wears daily soft lenses in both eyes, for a minimum of 2 days/week for 6 hours/day over the last month, and is willing to continue to do so during the study.
7. Have a current contact lens prescription. 8. Best corrected visual acuity of 20/25-2 or better in each eye (Can achieve acceptable lens fit as well as visual acuity (VA) correctable to logMAR +0.10 or better in each eye with their habitual contact lens type).
9. History or current use of artificial tears at least once in the last 30 days.
10. Be literate and able to complete questionnaires independently. 11. Be able and willing to use the study drug and participate in all study assessments and visits.
12. Have sufficient hand strength, in the opinion of the Investigator, to be able to independently administer the study drug.
13. Have provided written informed consent. 14. If a female is of childbearing potential, they must not plan to get pregnant during the study.
Exclusion Criteria:
- Wearing soft CLs on an extended wear basis (i.e. overnight) or is a rigid gas permeable lens or hybrid lens wearer
- Patients with dry eye complaints that the investigator deems are not related to dry eyes will be discontinued at Visit 1.
- Using prescription eyedrops for the treatment of dry eye disease (ex. Steroids, Lifitegrast, Cyclosporine)
- Clinically significant ocular trauma.
- Active or Inactive ocular Herpes simplex or Herpes Zoster infection
- Ocular inflammation (uveitis, iritis, scleritis, episcleritis, keratitis, conjunctivitis) at the discretion of the investigator.
- Ocular infection (e.g., viral, bacterial, mycobacterial, protozoan or fungal infection or the cornea, conjunctiva, lacrimal gland, lacrimal sac or eyelids including hordeolum/stye).
- Severe (Grade 3 or 4) inflammation of the eyelid (e.g., blepharochalasis, staphylococcal blepharitis or seborrheic blepharitis)
- Eyelid abnormalities that significantly affect the lid function (e.g., entropion, ectropion, tumor, edema, blepharospasm, lagophthalmos, severe trichiasis, severe ptosis).
- Ocular surface abnormality that may compromise the corneal integrity (e.g., prior chemical burn, recurrent corneal erosion, corneal epithelial defect, Grade 3 corneal fluorescein staining, map dot fingerprint dystrophy, or the effect of any other ophthalmic medication that might in the opinion of the investigator compromise the ocular surface integrity).
- Have a systemic condition or disease not stabilized or judged by the Investigator to be incompatible with participation in the study or with the lengthier assessments required by the study (e.g., current systemic infection, uncontrolled autoimmune disease, uncontrolled immunodeficiency disease, history of myocardial infarction or heart disease, etc.)
- Have had nasal or sinus surgery (including history of application of nasal cautery) or significant trauma to these areas
- Be currently treated with nasal continuous positive airway pressure
- Have any untreated nasal infection at Visit 1
- Have a vascularized polyp, severely deviated septum, chronic recurrent nosebleeds, or severe nasal obstruction.
- Have current concomitant use of a nicotinic acetylcholine receptor agonist [Nicoderm®, Nicorette®, Nicotrol NS® (nicotine), Tabex®, Desmoxan® (cytisine), and Chantix® (varenicline)] within the previous 30 days of Visit 1 and during the treatment period.
- Use of topical presecription ophthalmic medications including cyclosporine, liftegrast, steroids, non-steroidal anti-inflammatory drugs, anti-glaucoma medications within 7 days of screening or during study period.
- Prescription and OTC ophthalmic mast cell stabilizers and antihistamines within 21 days of screening and throughout study period (systemic permitted.)
- Have a known hypersensitivity to any of the procedural agents or study drug components
- Have active or uncontrolled, severe at the discretion of the investigator: (a) Systemic allergy, (b) Chronic seasonal allergies at risk of being active during the study treatment period, (c) Rhinitis or sinusitis requiring treatment such as antihistamines, decongestants, oral or aerosol steroids at the Screening Visit or be expected to require treatment during the treatment period of the study
- Be currently enrolled in an investigational drug or device study or have used an investigational drug or device within 30 days prior to Visit 1 and during the treatment period.
- Be a female who is pregnant, nursing, or planning a pregnancy at Visit 1. Be a woman of childbearing potential who is not using an acceptable means of birth control; acceptable methods of contraception include: hormonal - oral, implantable, injectable, or transdermal contraceptives; mechanical - spermicide in conjunction with a barrier such as a diaphragm or condom; IUD; or surgical sterilization of partner.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: OC-01 (varenicline 0.6mg/ml) nasal spray
Intranasal delivery of OC-01 nasal spray twice daily (BID)
|
Intranasal delivery of OC-01 nasal spray twice daily (BID)
|
Placebo Comparator: Placebo (vehicle) nasal spray
Intranasal delivery of placebo vehicle nasal spray twice daily (BID)
|
Intranasal delivery of Placebo (vehicle) nasal spray twice daily (BID)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
CLDEQ-8 scores at 4 weeks
Time Frame: 4 weeks
|
Mean change in CLDEQ-8 scores from baseline to week 4
|
4 weeks
|
Contact lens wear time at 4 weeks
Time Frame: 4 weeks
|
Mean change in comfortable wear time, overall wear time, and utilization of artificial tears from baseline to week 4 as measured by virtual daily log
|
4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
CLDEQ-8 scores at 8 weeks
Time Frame: 8 weeks
|
Mean change in CLDEQ-8 scores from baseline overtime through Week 8
|
8 weeks
|
Contact lens wear time at 8 weeks
Time Frame: 8 weeks
|
Mean change in comfortable wear time, overall wear time, and utilization of artificial tears from baseline overtime through Week 8 as measured by virtual daily log
|
8 weeks
|
Automated tear breakup time
Time Frame: 8 weeks
|
Mean change of automated tear film surface quality breakup time (TFSQ-BUT) over contact lenses from baseline overtime through week 8
|
8 weeks
|
Tearscope tear breakup time
Time Frame: 8 weeks
|
Mean change in non-invasive tear break up time (NIBUT) from baseline overtime through week 8 as measure and rated by Tearscope Plus
|
8 weeks
|
Vital staining score
Time Frame: 8 weeks
|
Mean change in vital staining overall score after lens removal from baseline overtime to week 8 as measured by masked evaluator
|
8 weeks
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Eye Diseases
- Lacrimal Apparatus Diseases
- Keratoconjunctivitis
- Conjunctivitis
- Conjunctival Diseases
- Keratitis
- Corneal Diseases
- Dry Eye Syndromes
- Keratoconjunctivitis Sicca
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Cholinergic Agents
- Nicotinic Agonists
- Cholinergic Agonists
- Varenicline
Other Study ID Numbers
- OP-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dry Eye
-
Gordon Schanzlin New VisionCompletedDry Eye | Dry Eye Disease | Evaporative Dry Eye | Kerato Conjunctivitis Sicca | Evaporative Dry Eye Disease | Dry Eye, EvaporativeUnited States
-
Kao (Taiwan) CorporationChang Gung Memorial HospitalCompletedEye Fatigue | Dry Eye SymptomTaiwan
-
Alcon ResearchCompletedVisual Performance | Dry Eye Symptoms
-
Alcon ResearchCompletedModerate to Severe Dry Eye
-
Singapore National Eye CentreCompleted
-
AllerganCompletedDry Eye Syndrome | Dry Eye DiseaseUnited States
-
Senju Pharmaceutical Co., Ltd.CompletedDry Eye Syndrome | Dry Eye DiseaseUnited States
-
Bausch & Lomb IncorporatedCompletedDry Eye Disease (DED)United States
-
Centre for Contact Lens ResearchCoopervision, Inc.CompletedContact Lens Related Dry EyeCanada
-
Singapore National Eye CentreCompleted
Clinical Trials on OC-01 (varenicline 0.6mg/ml) Nasal Spray
-
Brandon BaartmanRecruiting
-
Oyster Point Pharma, Inc.CompletedLong Term Follow up Dry Eye DiseaseUnited States
-
Vance Thompson Vision NDCompleted
-
Oyster Point Pharma, Inc.Completed
-
Oyster Point Pharma, Inc.CompletedNeurotrophic KeratopathyUnited States
-
Oyster Point Pharma, Inc.CompletedDry Eye DiseaseUnited States
-
Vance Thompson Vision - MTNot yet recruiting
-
Oyster Point Pharma, Inc.CompletedHealthy SubjectsUnited States
-
Ji Xing Pharmaceuticals (Shanghai) Co., Ltd.Oyster Point Pharma, Inc.Completed
-
Oyster Point Pharma, Inc.CompletedDry Eye Disease (DED)United States